One of the New Multiple Sclerosis Drugs being looked at is Daclizumab. It seems to work by targeting a single and specific molecule on immune cells, and in the process quiets the abnormal immune reactions experienced by MS patients.  MS causes the immune system to attack the nerves in the brain and spinal cord, leaving the patient unusually tired, weak, and in pain. Other “weird” sensations follow like tingling and high sensitivity to touch. Vision impairment is also common.

Daclizumab is one of the multiple sclerosis drugs in development stages currently. It is already approved by the FDA for use in preventing rejection of organ transplants, but has recently been studied to see if it can be added to the list of Multiple Sclerosis drugs approved by the FDA.

In two small trial studies, it has been confirmed that adding Daclizumab to interferon-beta therapy relieved symptoms in patients suffering relapse.  …